Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Eosinophilic Esophagitis | Harrisburg, Pennsylvania, U.S.
Previous Study | Return to List | Next Study

A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis (VOYAGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04682639
Recruitment Status : Recruiting
First Posted : December 24, 2020
Last Update Posted : September 5, 2021
Sponsor:
Information provided by (Responsible Party):
Arena Pharmaceuticals

Brief Summary:
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.

Condition or disease Intervention/treatment Phase
Eosinophilic Esophagitis Drug: Etrasimod Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis
Actual Study Start Date : February 23, 2021
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : February 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Etrasimod Dose 1 Drug: Etrasimod
Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.
Other Name: APD334

Experimental: Etrasimod Dose 2 Drug: Etrasimod
Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.
Other Name: APD334

Placebo Comparator: Placebo
Participants will receive etrasimod matching placebo tablet during the Double-Blind Treatment Period and etrasimod tablet during the Extension Treatment Period.
Drug: Placebo
Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.

Drug: Etrasimod
Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.
Other Name: APD334




Primary Outcome Measures :
  1. Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) [ Time Frame: Baseline to Week 16 ]

Secondary Outcome Measures :
  1. Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Score [ Time Frame: Baseline to Week 16 ]
    The DSQ is used to measure the intensity of dysphagia. DSQ scores can range from 0 to 84, with a higher score indicating more-frequent or more-severe dysphagia.

  2. Absolute Change From Baseline in Esophageal PEC [ Time Frame: Baseline to Week 16 ]
  3. Proportion of Participants With Esophageal PEC <15 Eosinophils per High Powered Field (eos/hpf) [ Time Frame: Baseline to Week 16 ]
  4. Proportion of Participants With Esophageal PEC ≤ 6 eos/hpf [ Time Frame: Baseline to Week 16 ]
  5. Number and Severity of Adverse Events (Double-Blind Treatment Period and Extension Treatment Period) [ Time Frame: Up to approximately 56 weeks (24 weeks of Double-Blind Treatment Period, 28 weeks of Extension Treatment Period, and 4 weeks of Safety Follow-Up Period) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have histologically active eosinophilic esophagitis (EoE) with an esophageal peak eosinophil count (PEC) of ≥ 15 eosinophils per high powered field (eos/hpf)
  • Have dysphagia, defined as solid food going down slowly or getting stuck in the throat with an average frequency of ≥ 2 episodes per week over 2 weeks during the Screening period

Inclusion Criteria for the Extension Treatment Period

  • Completion of the Week 24 study visit [including esophagogastroduodenoscopy (EGD)]
  • Compliance with study procedures during the Double-Blind Treatment Period as assessed by the Investigator
  • No notable safety concerns during the Double-Blind Treatment Period, as determined by the Investigator
  • Willing to comply with all study visits and procedures for the Extension Treatment Period

Exclusion Criteria:

  • History of any of the non-EoE conditions or procedures that may interfere with the evaluation of or affect the histologic (eg eosinophilic gastroenteritis), endoscopic (eg, high-grade esophageal stenosis), or symptom endpoints (eg, esophageal resection) of the study
  • Undergone dilation of an esophageal stricture within 12 weeks prior to Screening EGD
  • Use of corticosteroids for the treatment of EoE within 8 weeks prior to Screening EGD
  • Discontinue, initiate, or change dosing (dosage/frequency) of the following therapies for EoE within 8 weeks prior to Screening EGD. Participants on any of the following therapy need to stay on a stable regimen during study participation:

    1. Elemental diet
    2. EoE food trigger elimination diet
    3. Proton pump inhibitor (PPI) therapy
  • Used any immunotherapy/desensitization including oral immunotherapy (OIT) or sublingual immunotherapy (SLIT) within 12 months prior to the Screening EGD. Note: Stable (ie, ≥ 6 months prior to the Screening EGD) subcutaneous immunotherapy (SCIT) is permitted. Participants on SCIT need to stay on a stable treatment during study participation
  • Used any protocol-specified immunomodulatory therapies within the protocol-specified timeframe prior to Baseline (eg, dupilumab, benralizumab, omalizumab, or infliximab within 12 weeks; a sphingosine-1-phosphate receptor modulator at any time)
  • Use of any investigational agent or device within 12 weeks prior to Baseline
  • Females who are pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04682639


Contacts
Layout table for location contacts
Contact: Arena CT.gov Administrator +1 855-218-9153 ct.gov@arenapharm.com

Locations
Show Show 56 study locations
Sponsors and Collaborators
Arena Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Arena CT.gov Administrator Arena Pharmaceuticals
Layout table for additonal information
Responsible Party: Arena Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04682639    
Other Study ID Numbers: APD334-206
2020-003226-23 ( EudraCT Number )
First Posted: December 24, 2020    Key Record Dates
Last Update Posted: September 5, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Arena Pharmaceuticals:
Eosinophilic esophagitis
Esophageal eosinophilia
Etrasimod
APD334
EoE
Eosinophilic oesophagitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Esophagitis
Eosinophilic Esophagitis
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Gastroenteritis
Eosinophilia
Leukocyte Disorders
Hematologic Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases